INTERFERON, IMMUNITY AND LATENT VIRUSES

干扰素、免疫和潜伏病毒

基本信息

批准号：
3480386
负责人：
THOMAS C MERIGAN
金额：
$ 41.26万
依托单位：
STANFORD UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
1978
资助国家：
美国
起止时间：
1978-06-01 至 1993-05-31
项目状态：
已结题

项目摘要

Our group will continue our studies directed to the understanding and control of latent human herpesvirus infections. We will focus on herpes simplex and human cytomegalovirus. For herpes simplex infection, we will study herpes genitalis in both humans and the guinea pig model of infection. We will continue to study gamma interferon as a correlate of disease containment in both systems as well as investigating the possibility of augmenting immunity conferred by isolated viral glycoproteins with immunomodulators such as interleukin-2. For human cytomegalovirus, we will continue to study the human immune response to two glycoproteins identified in the previous granting period. One glycoprotein is 86 kDa (p86) and the other is a complex of glycoproteins of 130 and 55 Da (p130/55). Our aim is to establish whether humoral and cellular immune responses to these specific glycoproteins correlate with protective immunity. We will also analyse the importance of gamma interferon in human cytomegalovirus infection to determine whether it correlates, as in herpes labialis, with containment of virus. We will examine whether it correlates, as in herpes labialis, with containment of virus. We will examine whether gamma interferon contributes to immunopathology of human cytomegalovirus infection in allograft recipients. Finally we will develop anti- idiotype monoclonal antibodies to the murine monoclonal antibodies with virus neutralizing activity described in our laboratory. We will use these anti-idiotype monoclonals as possible adjuvants for immunization with either the p86 or p130/55 as well as new probes for studying the regulation of the immune response following human cytomegalovirus infection. We will also use them to attempt to identify a cellular receptor for human cytomegalovirus.

我们的小组将继续我们的研究直接涉及理解并控制潜在的人疱疹病毒感染。我们将集中精力在单纯疱疹和人类巨细胞病毒上。对于疱疹单纯性感染，我们将研究两个人的疱疹生殖器和豚鼠感染模型。我们将继续学习伽马干扰素作为疾病遏制的相关性系统以及研究增加的可能性由分离的病毒糖蛋白赋予的免疫力免疫调节剂，例如白介素2。对于人类巨细胞病毒，我们将继续研究人类对以前确定的两种糖蛋白的免疫反应授予期。一种糖蛋白是86 kDa（p86），另一个是 130和55 DA的糖蛋白的复合物（P130/55）。我们的目标是要确定是否有体液和细胞免疫反应这些特定的糖蛋白与保护性免疫相关。我们还将分析伽马干扰素在人类巨细胞病毒感染，以确定是否与疱疹中的疱疹一样，与病毒的遏制相关。我们将检查它是否像Labialis一样与病毒的控制。我们将检查伽马干扰素是否有助于人类巨细胞病毒的免疫病理学同种异体接受者感染。最后，我们将发展反对白痴单克隆抗体的单克隆抗体病毒中和活性的抗体在我们的实验室。我们将使用这些抗IDiotype单克隆人作为 p86或 P130/55以及研究调节的新探针人类巨细胞病毒感染后的免疫反应。我们还将使用它们尝试识别一个细胞受体人类巨细胞病毒。